Peptide Antibody Capture Agents for Stable Anti-gp41 Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing HIV diagnostic assays face challenges due to polyclonal diversity of antibodies, batch-to-batch variability of chimeric recombinant proteins, and performance issues in harsh environments, necessitating improved compositions and assays for accurate detection of anti-gp41 antibodies.
Innovation Solution
Development of chemically synthesized capture agents, known as Protein-Catalyzed Capture Agents (PCC Agents), designed to address polyclonal diversity through iterative in situ click chemistry, with specific binding to anti-gp41 antibodies, comprising anchor, secondary, tertiary, and quaternary ligands, and featuring thermal stability for point-of-care diagnostics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chimeric recombinant proteins are used as capture agents, then antibody detection is achieved, but batch-to-batch variability and shelf life limitations occur
Solution Approach 1:
The patent uses synthetic peptide sequences that copy the binding function of chimeric recombinant proteins without the biological reagent limitations. The synthetic peptides are designed to mimic the antigen-binding regions of gp41, providing consistent performance across batches without the shelf life and variability issues of biological proteins.
Solution Approach 2:
The patent changes the chemical nature of the capture agent from biological protein to synthetic peptide, fundamentally altering the stability parameters. This parameter change enables the capture agent to maintain consistent binding activity across different batches and storage conditions, resolving the reliability-stability contradiction.
2Measurement precision
If chimeric recombinant proteins are used, then anti-gp41 antibody detection is enabled, but polyclonal diversity causes large variations in assay performance
Solution Approach 1:
The patent segments the gp41 protein into specific peptide sequences (residues 600-612 and other conserved regions) that are independently synthesized. This segmentation allows each peptide to be optimized for binding to specific antibody subsets, thereby capturing polyclonal diversity more effectively and improving detection precision across different patient populations.
Solution Approach 2:
The patent creates a composite capture system using multiple synthetic peptides that collectively represent different epitopes on gp41. This composite approach enables the assay to detect a broader range of anti-gp41 antibodies, improving both precision and adaptability by accommodating polyclonal diversity.
3Reliability
If chimeric recombinant proteins are used for detection, then HIV diagnosis is achieved, but performance deteriorates in harsh physical environments
Solution Approach 1:
The patent employs synthetic peptides that are chemically stable and resistant to degradation under harsh conditions. These synthetic objects replace fragile biological proteins, maintaining diagnostic reliability in field settings without refrigeration while being cost-effective and easy to store.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PCC Agents provide stable and selective detection of anti-gp41 antibodies across varying temperatures and conditions, enhancing the accuracy and reliability of HIV diagnosis, particularly in environments lacking refrigeration.
Implementation Method 1
high-affinity, highly selective molecular moieties that recognize anti-gp41 antibodies
Implementation Method 2
iterative in situ click chemistry
Data Source
AI summary
The present application provides stable peptide-based antibody capture agents and methods of use as detection and diagnosis agents. The application further provides methods of manufacturing antibody capture agents using iterative on-bead in situ click chemistry.